BioRestorative Therapies
BRTX
12 hedge funds and large institutions have $483K invested in BioRestorative Therapies in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0.8% more ownership
Funds ownership: 6.63% → 7.43% (+0.8%)
8% less funds holding
Funds holding: 13 → 12 (-1)
11% less capital invested
Capital invested by funds: $541K → $483K (-$58K)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$260K |
| 2 |
Renaissance Technologies
New York
|
+$38.3K |
| 3 |
Two Sigma Investments
New York
|
+$28K |
| 4 |
Morgan Stanley
New York
|
+$15.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$154K |
| 2 |
Mariner
Overland Park,
Kansas
|
-$46.7K |
| 3 |
SG
StoneX Group
New York
|
-$41.5K |
| 4 |
Two Sigma Advisers
New York
|
-$34.3K |
| 5 |
HF
HRT Financial
New York
|
-$21K |
BRTX Hedge Fund Activity: Q1 2024 in Review
12 of the 6,948 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2024, worth a combined $483K — down 11% from $541K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BRTX and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $260K. The largest seller was Vanguard Group, cutting an estimated $154K.
- 12 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2024, down from 13 in Q4 2023.
- Funds reported $483K of BioRestorative Therapies stock for Q1 2024, down 11% quarter-over-quarter.
- 4 funds opened new BioRestorative Therapies positions in Q1 2024 and 5 closed out, a net change of -1 holder.
- The largest BioRestorative Therapies buyer in Q1 2024 was Sabby Management, an estimated $260K added.
- The largest BioRestorative Therapies seller in Q1 2024 was Vanguard Group, an estimated $154K sold.
Based on aggregated 13F filings for Q1 2024.